Journal article
Fitness loss under amino acid starvation in artemisinin-resistant Plasmodium falciparum isolates from Cambodia
- Abstract:
-
Artemisinin is the most rapidly effective drug for Plasmodium falciparum malaria treatment currently in clinical use. Emerging artemisinin-resistant parasites pose a great global health risk. At present, the level of artemisinin resistance is still relatively low with evidence pointing towards a trade-off between artemisinin resistance and fitness loss. Here we show that artemisinin-resistant P. falciparum isolates from Cambodia manifested fitness loss, showing fewer progenies during the intr...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
+ National Institutes of Health
More from this funder
Funding agency for:
Bunditvorapoom, D
Grant:
D43TW006571
+ Royal Golden Jubilee Ph.D. Program
More from this funder
Funding agency for:
Kochakarn, T
Grant:
PHD/0204/2552
Bibliographic Details
- Publisher:
- Nature Research Publisher's website
- Journal:
- Scientific Reports Journal website
- Volume:
- 8
- Article number:
- 12622
- Publication date:
- 2018-08-22
- Acceptance date:
- 2018-07-31
- DOI:
- EISSN:
-
2045-2322
- ISSN:
-
2045-2322
- Pmid:
-
30135481
- Source identifiers:
-
824670
Item Description
- Pubs id:
-
pubs:824670
- UUID:
-
uuid:91173250-19ad-407c-be50-0b8fcd5978e6
- Local pid:
- pubs:824670
- Deposit date:
- 2018-09-14
Terms of use
- Copyright holder:
- Bunditvorapoom, et al
- Copyright date:
- 2018
- Notes:
- © Bunditvorapoom, et al 2018. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record